An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial'
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms W-JHS NHL02-A study
- 16 Apr 2019 Status changed from not yet recruiting to recruiting.
- 23 Oct 2018 New trial record